DB:2GT

Stock Analysis Report

Applied Genetic Technologies

Executive Summary

Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases.


Snowflake Analysis

Flawless balance sheet with limited growth.

Share Price & News

How has Applied Genetic Technologies's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 2GT's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-13.3%

2GT

0.4%

DE Biotechs

-0.9%

DE Market


1 Year Return

76.3%

2GT

10.0%

DE Biotechs

12.8%

DE Market

Return vs Industry: 2GT exceeded the German Biotechs industry which returned 10% over the past year.

Return vs Market: 2GT exceeded the German Market which returned 12.8% over the past year.


Shareholder returns

2GTIndustryMarket
7 Day-13.3%0.4%-0.9%
30 Day-10.3%-3.2%-0.4%
90 Day113.1%4.6%2.3%
1 Year76.3%76.3%10.3%10.0%16.3%12.8%
3 Year-24.2%-24.2%49.4%47.8%15.8%5.7%
5 Year-72.6%-72.6%13.9%11.5%19.7%3.3%

Price Volatility Vs. Market

How volatile is Applied Genetic Technologies's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Applied Genetic Technologies undervalued compared to its fair value and its price relative to the market?

1.62x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 2GT's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 2GT's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 2GT is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: 2GT is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 2GT's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 2GT is good value based on its PB Ratio (1.6x) compared to the DE Biotechs industry average (3.5x).


Next Steps

Future Growth

How is Applied Genetic Technologies forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

12.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 2GT is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 2GT is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 2GT is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 2GT's revenue (73% per year) is forecast to grow faster than the German market (5.2% per year).

High Growth Revenue: 2GT's revenue (73% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 2GT's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Applied Genetic Technologies performed over the past 5 years?

7.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 2GT is currently unprofitable.

Growing Profit Margin: 2GT is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 2GT is unprofitable, but has reduced losses over the past 5 years at a rate of 7.7% per year.

Accelerating Growth: Unable to compare 2GT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 2GT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).


Return on Equity

High ROE: 2GT has a negative Return on Equity (-32.02%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Applied Genetic Technologies's financial position?


Financial Position Analysis

Short Term Liabilities: 2GT's short term assets ($64.7M) exceed its short term liabilities ($14.9M).

Long Term Liabilities: 2GT's short term assets ($64.7M) exceed its long term liabilities ($7.3M).


Debt to Equity History and Analysis

Debt Level: 2GT is debt free.

Reducing Debt: 2GT has not had any debt for past 5 years.


Balance Sheet

Inventory Level: 2GT has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if 2GT's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 2GT has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: 2GT has sufficient cash runway for 1.4 years if free cash flow continues to reduce at historical rates of -23.9% each year.


Next Steps

Dividend

What is Applied Genetic Technologies's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.3%markettop25%3.6%industryaverage1.0%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate 2GT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 2GT's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 2GT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 2GT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 2GT's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

17.9yrs

Average management tenure


CEO

Sue Washer (58yo)

17.9yrs

Tenure

US$1,052,232

Compensation

Ms. Susan B. Washer, also known as Sue, has been the President and Chief Executive Officer of Applied Genetic Technologies Corporation since March 2002. Ms. Washer is an experienced entrepreneur with a str ...


CEO Compensation Analysis

Compensation vs Market: Sue's total compensation ($USD1.05M) is above average for companies of similar size in the German market ($USD413.13K).

Compensation vs Earnings: Sue's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Susan Washer
President17.9yrsUS$1.05m0.11% $139.9k
Mark Shearman
Chief Scientific Officer4.7yrsUS$772.64kno data
Matthew Feinsod
Executive VP of Global Strategy & Development0.5yrsUS$820.25k0.23% $276.1k
Nicholas Muzyczka
Co-Founder21.1yrsno datano data
Barry Byrne
Co-Founder21.1yrsno datano data
William Hauswirth
Co-Founder & Member of Ophthalmology Scientific Advisory Board0yrsno datano data
Richard Samulski
Co-Founder21.1yrsno datano data
Terence Flotte
Co-Founder21.1yrsno datano data
William Sullivan
Chief Financial Officer2.5yrsUS$920.61k0.012% $14.8k
Brian Krex
General Counsel0.9yrsno datano data

17.9yrs

Average Tenure

51yo

Average Age

Experienced Management: 2GT's management team is seasoned and experienced (17.9 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Susan Washer
President17.9yrsUS$1.05m0.11% $139.9k
William Hauswirth
Co-Founder & Member of Ophthalmology Scientific Advisory Board0yrsno datano data
Edward Hurwitz
Independent Director7.3yrsUS$124.09k0.11% $135.3k
Anne VanLent
Independent Director3.5yrsUS$129.09kno data
Scott Koenig
Chairman of the Board15.8yrsUS$152.09k0.14% $168.7k
Ivana Magovcevic-Liebisch
Independent Director5.7yrsUS$132.09k0.012% $14.8k
David Birch
Member of Ophthalmology Scientific Advisory Board0yrsno datano data
William Aliski
Independent Director1.4yrsUS$162.28k0.034% $41.9k
Peter Campochiaro
Member of Ophthalmology Scientific Advisory Board0yrsno datano data
James Rosen
Independent Director9.9yrsUS$117.09k0.0040% $4.9k

7.3yrs

Average Tenure

58yo

Average Age

Experienced Board: 2GT's board of directors are considered experienced (7.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Applied Genetic Technologies Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Applied Genetic Technologies Corporation
  • Ticker: 2GT
  • Exchange: DB
  • Founded: 1999
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$132.548m
  • Listing Market Cap: US$122.024m
  • Shares outstanding: 24.78m
  • Website: https://www.agtc.com

Number of Employees


Location

  • Applied Genetic Technologies Corporation
  • 14193 NW 119th Terrace
  • Suite 10
  • Alachua
  • Florida
  • 32615
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
AGTCNasdaqGM (Nasdaq Global Market)YesCommon SharesUSUSDMar 2014
2GTDB (Deutsche Boerse AG)YesCommon SharesDEEURMar 2014

Biography

Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. The company’s advanced product candidates consist of three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials. The company also has initiated one preclinical program in otology and three preclinical programs in targeting central nervous system disorders, including one in adrenoleukodystrophy. Applied Genetic Technologies Corporation has collaboration agreements with Synpromics Limited and University of Florida; Bionic Sight, LLC; and Otonomy, Inc. The company was founded in 1999 and is headquartered in Alachua, Florida. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/23 23:20
End of Day Share Price2020/02/21 00:00
Earnings2019/12/31
Annual Earnings2019/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.